Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ensysce Biosciences, Inc. - Common Stock
(NQ:
ENSC
)
0.4142
-0.0098 (-2.31%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Ensysce Biosciences, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Ensysce Biosciences Secures IRB Approval of Final Phase of PF614-MPAR-102 Clinical Study
April 16, 2026
Via
ACCESS Newswire
Ensysce Biosciences Secures Second Financing From 2025 Agreement to Advance Breakthrough Pain Programs
April 07, 2026
Via
ACCESS Newswire
Ensysce Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results
March 30, 2026
Via
ACCESS Newswire
Ensysce Biosciences Initiates Live "Ask Me Anything" (AMA) Session Highlighting Growth and Future Plans
March 04, 2026
Via
ACCESS Newswire
Ensysce Biosciences Announces First Peer-Reviewed Clinical Publication Demonstrating Oral Overdose Protection with MPAR(R) Technology
March 03, 2026
Via
ACCESS Newswire
Rapid Dose Therapeutics (CSE: DOSE) (OTCQB: RDTCF) Advances QuickStrip™ Research Backed by NFL-Supported Clinical Evaluation – More Stocks Inside
February 27, 2026
Via
AB Newswire
Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
June 04, 2025
Via
ACCESS Newswire
Ensysce Biosciences Initiates Review of Strategic Alternatives to Enhance Shareholder Value
February 25, 2026
Via
ACCESS Newswire
Ensysce Biosciences Invited to Participate in Upcoming Scientific and Industry Events
February 23, 2026
Via
ACCESS Newswire
Ensysce Biosciences Expands Global Opioid Patent Portfolio
January 21, 2026
Via
ACCESS Newswire
Ensysce Biosciences Receives EU Patent Expanding its First-in-Class ADHD Therapy with Built-In Abuse and Overdose Protection
January 08, 2026
Via
ACCESS Newswire
Ensysce Biosciences Issues Annual Shareholder Letter
January 05, 2026
Via
ACCESS Newswire
Ensysce Biosciences Achieves Major Milestone with Initiation of Enrollment in Pivotal Phase 3 Trial of PF614, Its Next-Generation Opioid
December 09, 2025
Via
ACCESS Newswire
Ensysce Biosciences Announces Broader Patent Protection for Groundbreaking MPAR(R) Overdose Protection Technology
December 02, 2025
Via
ACCESS Newswire
Ensysce Biosciences Receives Positive FDA Feedback on PF614 Manufacturing Approach
November 20, 2025
Via
ACCESS Newswire
Ensysce Biosciences Secures $4 Million Financing, Unlocking Up to $20 Million in Total Financing to Advance Breakthrough Pain Programs
November 17, 2025
Via
ACCESS Newswire
Ensysce Biosciences Reports Third Quarter 2025 Financial Results
November 14, 2025
Via
ACCESS Newswire
Ensysce Biosciences Releases Symposium Highlights from PAINWeek 2025
October 10, 2025
Via
ACCESS Newswire
Ensysce Biosciences Showcases Urgent Need for Safer Opioids at PAINWeek 2025 Symposium
September 04, 2025
Via
ACCESS Newswire
Ensysce Biosciences' Geoff Birkett to Chair the Fierce New Product Planning Summit 2025
August 19, 2025
Via
ACCESS Newswire
Ensysce Biosciences Reports Second Quarter 2025 Financial Results and Latest Program Updates
August 13, 2025
Via
ACCESS Newswire
Ensysce Biosciences Advances Breakthrough Opioid With Built-In Overdose Protection Following Positive FDA Feedback
July 31, 2025
Via
ACCESS Newswire
Ensysce Biosciences Initiates Pivotal Phase 3 Study of PF614 - A Next-Generation Opioid - Designed to Deliver Powerful Pain Relief and Reduce Abuse
July 16, 2025
Via
ACCESS Newswire
Ensysce Biosciences Accelerates PF614-MPAR-102 Study with Full Enrollment of Part 2
June 24, 2025
Via
ACCESS Newswire
Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
June 11, 2025
Via
ACCESS Newswire
Ensysce Biosciences Reports First Quarter 2025 Financial Results
May 13, 2025
Via
ACCESS Newswire
Ensysce Biosciences Bolsters Management Team with Regulatory Expert
May 12, 2025
Via
ACCESS Newswire
Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds
April 24, 2025
Via
ACCESS Newswire
Ensysce Biosciences, Inc. Announces Exercise of Warrants for $2.2 Million Gross Proceeds
April 23, 2025
Via
ACCESS Newswire
Ensysce Biosciences Receives U.S. Patent for Groundbreaking Treatment of Opioid Use Disorder
April 23, 2025
Via
ACCESS Newswire
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
